These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9035091)

  • 1. Commissioner Kessler's agbio legacy.
    Hoyle R
    Nat Biotechnol; 1997 Jan; 15(1):2. PubMed ID: 9035091
    [No Abstract]   [Full Text] [Related]  

  • 2. The FDA: a dromedary tale.
    Nat Biotechnol; 1997 Jan; 15(1):1. PubMed ID: 9035089
    [No Abstract]   [Full Text] [Related]  

  • 3. Kessler's departure from FDA gets mixed response.
    Fox JL
    Nat Biotechnol; 1997 Jan; 15(1):9. PubMed ID: 9035093
    [No Abstract]   [Full Text] [Related]  

  • 4. The end of big government?
    Miller HI
    Nat Biotechnol; 1997 Feb; 15(2):111. PubMed ID: 9035118
    [No Abstract]   [Full Text] [Related]  

  • 5. Kessler's legacy: unfinished reform.
    Stone R
    Science; 1996 Dec; 274(5293):1603-4. PubMed ID: 8984623
    [No Abstract]   [Full Text] [Related]  

  • 6. Biotechnology food standards hunger for scientific rationale.
    Miller HI
    Trends Biotechnol; 2000 Jun; 18(6):232-3. PubMed ID: 10802557
    [No Abstract]   [Full Text] [Related]  

  • 7. Proposed rules issued for bioengineered foods.
    Formanek R
    FDA Consum; 2001; 35(2):9-11. PubMed ID: 11444252
    [No Abstract]   [Full Text] [Related]  

  • 8. McClellan's FDA: boon to industry, consumers, or both? New FDA chief plans to speed drug approval and reduce costs.
    Ault A
    Lancet; 2003 Aug; 362(9381):379-80. PubMed ID: 12911016
    [No Abstract]   [Full Text] [Related]  

  • 9. Regulatory considerations in the development of protein pharmaceuticals.
    Beatrice MG
    Pharm Biotechnol; 2002; 14():405-56. PubMed ID: 12189729
    [No Abstract]   [Full Text] [Related]  

  • 10. New FDA Commissioner sees challenges, opportunities.
    Lewis C
    FDA Consum; 2003; 37(1):9. PubMed ID: 12625298
    [No Abstract]   [Full Text] [Related]  

  • 11. A changed FDA?
    Lancet; 2008 Aug; 372(9637):420. PubMed ID: 18692698
    [No Abstract]   [Full Text] [Related]  

  • 12. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights October-December 2015.
    Office of Health & Constituent Affairs U.S. Food and Drug Administration
    Am J Health Syst Pharm; 2016 Mar; 73(5):267. PubMed ID: 26896495
    [No Abstract]   [Full Text] [Related]  

  • 13. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fresh from the biologic pipeline.
    Osborne R
    Nat Biotechnol; 2009 Mar; 27(3):222-5. PubMed ID: 19270664
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA transgenic animal guidance finally surfaces.
    Fox JL
    Nat Biotechnol; 2008 Nov; 26(11):1205-7. PubMed ID: 18997745
    [No Abstract]   [Full Text] [Related]  

  • 16. Fight food. Interview by Brendan Borrell.
    Beachy R
    Sci Am; 2011 Apr; 304(4):80-3. PubMed ID: 21495487
    [No Abstract]   [Full Text] [Related]  

  • 17. Fields of gold.
    Nature; 2013 May; 497(7447):5-6. PubMed ID: 23646363
    [No Abstract]   [Full Text] [Related]  

  • 18. CBER status on reform initiatives: industry reactions and comments.
    Page M
    Food Drug Law J; 1997; 52(2):193-6. PubMed ID: 10557559
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of new regulations for pediatric labeling by the Food and Drug Administration.
    Buck ML
    Pediatr Nurs; 2000; 26(1):95-6. PubMed ID: 12026326
    [No Abstract]   [Full Text] [Related]  

  • 20. Genetically engineered organic food?
    Hoyle R
    Nat Biotechnol; 1998 Mar; 16(3):214. PubMed ID: 9527990
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.